Immune Modulation Therapy for Pompe Disease

NCT02525172 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Pompe Disease

Interventions

DRUG: Rituximab
DRUG: intravenous immune globulin
DRUG: Bortezomib
DRUG: Methotrexate

Sponsor

National Taiwan University Hospital